Stribild
Drug
Gilead Sciences Inc
Total Payments
$2.6M
Transactions
68
Doctors
12
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $245,522 | 2 | 0 |
| 2023 | $231,404 | 4 | 0 |
| 2022 | $341,705 | 5 | 2 |
| 2021 | $800.00 | 1 | 1 |
| 2020 | $484,255 | 8 | 4 |
| 2019 | $300,500 | 11 | 7 |
| 2018 | $659,402 | 19 | 0 |
| 2017 | $290,515 | 18 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 53 | 99.8% |
| Consulting Fee | $3,800 | 4 | 0.1% |
| Food and Beverage | $591.54 | 11 | 0.0% |
Payments by Type
Research
$2.5M
53 transactions
General
$4,392
15 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Immediate Initiation of ART During "Hyperacute" and Acute HIV Infection | Gilead Sciences, Inc. | $767,964 | 0 |
| HIV infection, use of tenofovir and other antiretrovirals, and risk of fatal and non-fatal comorbidities: Cohort Study in Kaiser Permanente | Gilead Sciences, Inc. | $699,478 | 0 |
| Immediate Initiation of Antiretroviral Therapy During "Hyperacute" and Acute HIV Infection | Gilead Sciences, Inc. | $441,650 | 0 |
| A Randomized, Double-Blind, Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Women | Gilead Sciences, Inc. | $125,762 | 0 |
| Tolerability and acceptability of Stribild as PEP to prevent sexual acquisition of HIV-1 in high risk young men | Gilead Sciences Inc | $67,250 | 0 |
| A Phase IV open-label evaluation of safety, tolerability and acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-Tablet Regimen for non-occupational prophylaxis following potential exposure to HIV-1 | Gilead Sciences Inc | $60,000 | 0 |
| Advanced imaging detection of central nervous system changes associated with long-term efavirenz therapy | Gilead Sciences, Inc. | $54,671 | 0 |
| Treatment of Acute HIV Infection with the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate [Quad FDC Tablet]: A Study of Response to Therapy and HIV Pathogenesis | Gilead Sciences Inc | $50,000 | 0 |
| Treatment of Acute HIV Infection with the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate [Quad FDC Tablet]: A Study of Response to Therapy and HIV Pathogenesis | Gilead Sciences, Inc. | $50,000 | 0 |
| Survey study assessing prescribers knowledge, beliefs and behaviors regarding switching HIV treatment in patients with virologic suppression to simplified single tablet regimens | Gilead Sciences Inc | $46,425 | 0 |
| Change in Sleep Architecture and Neuropsychological Performance following Switch from Atripla to Stribild | Gilead Sciences, Inc. | $29,998 | 0 |
| Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals | Gilead Sciences, Inc. | $29,163 | 0 |
| Adherence & Health outcome differences amongst HIV infected patients prescribed a single tablet regimen (STR) versus multi tablet regimen (MTR). | Gilead Sciences, Inc. | $26,992 | 0 |
| An Open-Label Trial of STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) for ARV-naive HIV-2 Infected Adults in Dakar, Senegal | Gilead Sciences, Inc. | $23,723 | 0 |
| An Open-Label Trial of STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) for ARV-naive HIV-2 Infected Adults in Dakar, Senegal | Gilead Sciences Inc | $22,657 | 0 |
| A Randomized, Double-Blind, Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Women | Gilead Sciences Inc | $21,523 | 0 |
| Survey study assessing prescribers knowledge, beliefs and behaviors regarding switching HIV treatment in patients with virologic suppression to simplified single tablet regimens | Gilead Sciences, Inc. | $9,803 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | Gilead Sciences Inc | $9,421 | 0 |
| A Study of the Concordance of Knowledge and Beliefs Held by Patients Infected with HIV and Their Health Care Providers Regarding Single Tablet Regimens (STR). (KnaBSTR Study). | Gilead Sciences Inc | $6,439 | 0 |
| A Phase 3 Single Arm Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment | Gilead Sciences Inc | $5,175 | 0 |
Top Doctors Receiving Payments for Stribild
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $2.5M | 53 |
| , M.D | Pediatric Infectious Diseases | Lebanon, NH | $3,800 | 4 |
| , MD | Internal Medicine | Fort Lauderdale, FL | $121.25 | 1 |
| , MD | Family Medicine | Miami, FL | $121.25 | 1 |
| , MD | Family Medicine | Papillion, NE | $102.88 | 1 |
| , MD | Emergency Medicine | Elyria, OH | $87.44 | 1 |
| , M.D | Infectious Disease | Manhasset, NY | $67.12 | 1 |
| , M.D | Internal Medicine | Augusta, GA | $45.02 | 1 |
| , MD | Internal Medicine | Fort Lauderdale, FL | $20.43 | 1 |
| , M.D | Infectious Disease | Miami, FL | $19.93 | 1 |
| , M.D | Infectious Disease | Chicago, IL | $2.08 | 1 |
| , D.O | Infectious Disease | Chicago, IL | $2.07 | 1 |
| , MD | Infectious Disease | Chicago, IL | $2.07 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $2.3M
- Gilead Sciences Inc $290,515
Product Information
- Type Drug
- Total Payments $2.6M
- Total Doctors 12
- Transactions 68
About Stribild
Stribild is a drug associated with $2.6M in payments to 12 healthcare providers, recorded across 68 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $245,522 was paid across 2 transactions to 0 doctors.
The most common payment nature for Stribild is "Unspecified" ($2.5M, 99.8% of total).
Stribild is associated with 20 research studies, including "Immediate Initiation of ART During "Hyperacute" and Acute HIV Infection" ($767,964).